je.st
news
Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA
2014-11-25 16:58:52| Biotech - Topix.net
Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy . SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.
Tags: with
study
children
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||